Fig. 1From: A phase II study of the combination chemotherapy of bevacizumab and gemcitabine in women with platinum-resistant recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancerProgression-free survival (PFS) estimated using the Kaplan–Meier methodBack to article page